ENGOT EN20
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Description: This placebo controlled, double-blind trial assesses the effectiveness of Selinexor as maintenance treatment in women with P53 wild type, advanced or recurrent endometrial cancer
Study Phase: Phase 3
Principal Investigator: Dr Karen Cadoo
Further information
